Mast cell tumors in dogs.

What it is

Mast cell tumors (MCT) arise from mast cells — immune cells that normally sit in skin and connective tissue and release histamine in response to triggers. When a mast cell becomes malignant, the resulting mass can release degranulation-related signals that produce local swelling, itching, and sometimes systemic GI signs (vomiting, ulcers) in higher-grade or advanced cases.

MCTs can look like almost anything — a small bump, a swelling that comes and goes, a fast-growing mass, even a soft lump that looks deceptively benign. That visual variability is why fine-needle aspiration is the standard first step on any new skin mass.

Signs to watch for

• A skin mass that changes in size, color, or feel. Especially one that gets bigger, smaller, then bigger again — that 'waxing and waning' pattern is a classic MCT tell.
• Recurrent vomiting or loss of appetite. Higher-grade or metastatic MCT can release histamine systemically, irritating the GI tract.
• Bruising near the mass or a red 'flare' after handling. Mechanical disturbance can trigger localized degranulation (Darier's sign).

How veterinarians diagnose it

FNA + cytology of a representative mass gives a same-day answer in most cases — mast cells have distinctive granules that stain blue with standard cytology stains.

Once MCT is confirmed, the vet will typically aspirate a draining lymph node (even if it feels normal — 'normal' nodes still harbor mets ~25% of the time), and may recommend abdominal ultrasound and chest imaging for higher-grade or larger tumors.

Definitive grade (low/high under the 2-tier Kiupel system, or I/II/III under the older Patnaik) requires histopathology — the surgically removed tissue read by a pathologist.

What treatment usually looks like

• Wide surgical excision with 2–3 cm lateral margins and one fascial plane deep. Clean margins on a low-grade tumor are often curative.
• Radiation for incompletely excised low-grade tumors or as an adjunct for high-grade disease — typically delivered at a referral center.
• Toceranib (Palladia) or vinblastine-based chemotherapy for high-grade, recurrent, or metastatic disease. Toceranib is the canine-licensed tyrosine kinase inhibitor; c-KIT mutation testing can predict who responds best.
• Histamine blockers (H1 + H2 antagonists) before surgery or during therapy, to prevent degranulation-related complications.
• Palliative pain control for cases not pursuing definitive treatment.

Prognosis

Outcomes depend mostly on grade, stage, and completeness of excision. Low-grade tumors removed with clean margins are commonly cured — long-term survival is typical. High-grade tumors carry significantly worse prognoses with median survival often in the months range even with aggressive therapy, though individual variation is wide.

c-KIT internal tandem duplication (ITD) testing on the tumor identifies dogs who tend to respond to toceranib and informs prognosis. Ask your oncologist whether c-KIT testing makes sense for your case.

Questions to ask your vet

• What grade is the tumor — under which system, and how confident is the pathologist?
• Were the surgical margins clean? If not, what's the next step — re-excision or radiation?
• Did we aspirate the regional lymph node? Was there spread?
• Should we test for the c-KIT mutation?
• What signs of recurrence or systemic spread should I watch for?
• Is Palladia or chemotherapy appropriate, and what does the schedule look like?

Where to learn more

Veterinary teaching hospitals at most accredited US vet schools maintain owner-facing fact sheets on common cancers. Peer-reviewed journals — JAVMA, Veterinary and Comparative Oncology, Frontiers in Veterinary Science — are accessible through PubMed. The American College of Veterinary Internal Medicine (ACVIM) and the Veterinary Cancer Society publish consensus statements you can ask your vet to walk you through.

For clinical trials enrolling dogs with this diagnosis, see the SciRouter Vet trial finder — we index AVMA, NCI COTC, and twelve university registries.